Table 1 Patient characteristics and comorbidities; comparison of patients with and without QTc prolongation on EKG
From: Coronavirus disease 2019 (COVID-19) and QTc prolongation
Baseline characteristics | All patients (N = 279) | QTc prolongation (N = 69) | No QTc prolongation (N = 210) | P value |
|---|---|---|---|---|
Baseline QTc (ms) | 430 ± 18 | 431 ± 20 | 430 ± 19 | 0.72 |
Age | 62 ± 17 | 67 ± 17 | 60 ± 17 | 0.003 |
Sex | Â | Â | Â | Â |
Male, n (%) | 145 (52) | 39 (57) | 106 (51) | 0.383 |
Female, n (%) | 134 (48) | 30 (44) | 104 (50) | Â |
Race | Â | Â | Â | Â |
Caucasian, n (%) | 181 (65) | 40 (58) | 141 (68) | 0.097 |
African-American, n (%) | 82 (30) | 27 (39) | 55 (26) | Â |
Latino, n (%) | 13 (5) | 1 (1) | 12 (6) | Â |
Other, n (%) | 2 (1) | 1 (1) | 1 (1) | Â |
Hypertension, n (%) | 197 (70) | 53 (77) | 144 (67) | 0.192 |
Diabetes mellitus, n (%) | 101 (36) | 31 (45) | 70 (33) | 0.082 |
Cardiovascular disease, n (%) | 87 (31) | 33 (48) | 54 (26) | 0.001 |
Ischemic heart disease, n (%) | 55 (20) | 20 (29) | 35 (17) | 0.026 |
CHFrEF, n (%) | 13 (5) | 5 (7) | 8 (4) | 0.240 |
CHFpEF, n (%) | 27 (10) | 11 (16) | 16 (8) | 0.042 |
Atrial fibrillation, n (%) | 28 (10) | 11 (16) | 17 (8) | 0.060 |
Active cancer, n (%) | 12 (4) | 3 (4) | 9 (4) | 0.982 |
Stroke, n (%) | 33 (12) | 8 (12) | 25 (12) | 0.945 |
Chronic kidney disease, n (%) | 37 (13) | 16 (23) | 21 (10) | 0.005 |
ESRD on HD, n (%) | 11 (4) | 8 (12) | 3 (1) | < 0.001 |
Chronic liver disease, n (%) | 13 (5) | 6 (9) | 7 (3) | 0.062 |
Immunosuppressive state, n (%) | 19 (7) | 7 (10) | 12 (6) | 0.193 |
Home med: ACEi, n (%) | 62 (22) | 8 (11) | 54 (26) | 0.014 |
Home med: ARBs/ARNI, n (%) | 32 (12) | 8 (12) | 24 (11) | 0.970 |